PKZ-021CPRCE

PTO/SB/30 (09-03)

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attomey Docket Number

R. S.	Request
	For
Continu	ued Examination (RCE)
	Transmittal
Address to:	

Application Number 09/768189 January 23, 2001 Filing Date First Named Inventor Stuart B. LEVY 1616 Art Unit Commissioner for Patents P.O. Box 1450 Examiner Name B. P. Badio Alexandria, VA 22313-1450

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June

8, 1995, or to any design application.	
1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).	
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.	
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on	
ii. Other	
i. X Amendment/Reply iii. Information Disclosure Statement (IDS)	
iiAffidavit(s)/Declaration(s) ivOther	
2. Miscellaneous	
a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a	
period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)	
b. Other	
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.	
a. X The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 12-0080	
i. X RCE fee required under 37 CFR 1.17(e)	
ii. X Extension of time fee (37 CFR 1.136 and 1.17)	
<u> </u>	
iii. U Other	
b. Check in the amount of \$ enclosed	
c. Payment by credit card (Form PTO-2038 enclosed)	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
Name (Print/Type) Cynthia M. Soroos Registration No. (Attorney/Agent) 53,623	
Signature Date June 21, 2004	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL 981 583 272 US, in an envelope addressed to: MS RCE, Commissioner for Statents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: June 21, 2004 Signature:(Cynthia M. Soroos)	

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Stuart B. Levy and

Mark L. Nelson

Serial No.: 09/768,189

Filed: January 23, 2001

For: Tetracycline Compounds for Treatment of

CRYPTOSPORIDIUM PARVUM RELATED DISORDERS

Attorney Docket No.: PKZ-021CPRCE

MS RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Certificate of Express Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EL 981 583 272 US, in an envelope addressed to: MS ROE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date set forth below.

June 21, 2004

June 21, 2004

Date of Signature and of Mail Deposit

By:

Reg. No. 53,623

Agent for Applicants

Group Art Unit: 1616

Examiner: Barbara Badio

## AMENDMENT AND RESPONSE

Dear Sir:

This is in response to the Final Office Action mailed from the U.S. Patent and Trademark Office on May 22, 2003 (Paper No. 11) for the above referenced patent application. A request for the appropriate extension of time and the requisite fee is filed concurrently herewith.

Please amend the application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 8 of this paper.